Today, there are more than 800 medicines in development for diseases that disproportionately affect racial and ethnic communities. A new report from PhRMA explores these medicines that target these diseases and conditions, which not only affect these racial and ethnic communities at a higher rate, but are also associated with worse COVID-19 outcomes.